The Pathogenesis of Sickle Cell Nephropathy
The Pathogenesis of Sickle Cell Nephropathy
批准号:
7918027
负责人:
DAVID R ARCHER
金额:
$35.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-01 至 2012-08-31
关键词:
ATP phosphohydrolaseAcidsAdolescentAdultAffectAfrican AmericanAftercareAgeAlbuminsAlbuminuriaAnimal ModelAreaBiological MarkersBirthBloodBlood VesselsBone Marrow TransplantationChildChildhoodClinicClinicalClinical ManagementClinical ResearchComplicationCreatinineDataDehydrationDetectionDevelopmentDextransDiseaseDisease ProgressionExcretory functionExperimental Water DeprivationExtravasationFunctional disorderGlobinGlomerular CapillaryGlomerular Filtration RateGoalsHematopoiesisHematopoietic Stem Cell TransplantationHemoglobinHemoglobin SSHereditary DiseaseHispanic AmericansHistologyHumanImmunoglobulin GIndividualInjuryKidneyKidney DiseasesKidney FailureKidney GlomerulusKnowledgeLeadLesionLifeMeasuresMicroalbuminuriaModelingMolecularMusMutationPathogenesisPathway interactionsPatientsPermeabilityPlasma ProteinsPopulationPrevalencePreventionProteinsRegulationRenal Blood FlowRenal functionRenal glomerular diseaseReportingSerumSeverity of illnessSickle CellSickle Cell AnemiaSickle HemoglobinStem cell transplantTechniquesTestingTherapeuticTherapeutic InterventionTransforming Growth Factor betaTransplantationTubular formationUnited StatesUrineWateragedalpha-1-microglobulinaquaporin-2basebeta-2 Microglobulincohortconnective tissue growth factordesigndextrandisorder preventionfetalhemodynamicshuman diseasehydroxyureaimprovedkidney medullamouse modelnewsperipheral bloodpodocytepreventpublic health relevancerepairedresponserestorationsicklingsolutetreatment effecturea transporterurinary
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Sickle cell nephropathy is a common complication of sickle cell disease that affects both children and adults, and may lead to kidney failure. The mechanisms that cause kidney damage in sickle cell disease are not well understood. We will study kidney damage in a murine model of sickle cell disease that develops kidney injury that resembles human disease. We will investigate how sickle cell disease damages different areas of the kidneys: the glomerulus, causing protein leakage in the urine, renal insufficiency and kidney failure, and the kidney medulla which causes an inability to concentrate the urine, making the patients prone to dehydration. In the same animal model, we will study whether the renal damage described in our preliminary data and further defined in the first Aim can be reversed, ameliorated, or prevented by fully or partially restoring normal hematopoiesis after bone marrow transplantation. We will extend these studies in patients with sickle cell disease to investigate the ability of two primary therapies for sickle cell disease to prevent or repair sickle cell nephropathy. First, we will study if replacement of sickle hematopoiesis by hematopietic stem cell transplant can reverse or improve kidney damage that was already present in patients with sickle cell disease, and whether kidney damage progresses after transplantation. Then we will study the effects of hydroxyurea treatment in pediatric and adult sickle cell patients with early kidney disease to assess the ability of this agent to repair kidney function. In these cohorts of children and adults, we will study the effect of treatment on parameters of renal dysfunction and whether certain biomarkers of renal injury improve with treatment of the disease. We believe that by studying the renal response to two therapeutic interventions that modify the underlying disease, we will be able to determine which potential pathophysiological pathways are involved in early disease and late manifestations. This may allow us to design strategies to treat or prevent certain complications of the disease. Our goal is to understand the mechanisms of kidney damage in sickle cell disease and to determine if current therapies can repair or prevent progression of sickle kidney disease. We believe the combination of basic and clinical studies will enable us to contribute to the clinical management of the disease and the prevention of sickle cell nephropathy. PUBLIC HEALTH RELEVANCE: Sickle cell disease is one of the most common genetic diseases and affects ~100,000 individuals in the United States occurring in ~1:400 African-American and ~ 1:1200 Hispanic-American births each year. Kidney damage occurs early in life and worsens through adulthood with approximately 80% of patients over 40 years having renal disease. Even though sickle nephropathy is one of the most prevalent and potentially dangerous complications of sickle cell disease the mechanisms underlying its development are poorly understood and will thus be the focus of this proposal. Our goal is to find news treatment for this potentially devastating condition.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Small Molecule Therapeutics for Sickle Cell Anemia
-
批准号:10601679
-
项目类别:
-
资助金额:$54.72万
-
财政年份:2023
-
负责人:DAVID R ARCHER
-
依托单位:
Impaired Collateral Vessel Formation in Sickle Cell Disease
-
批准号:9751364
-
项目类别:
-
资助金额:$60.53万
-
财政年份:2016
-
负责人:DAVID R ARCHER
-
依托单位:
Impaired Collateral Vessel Formation in Sickle Cell Disease
-
批准号:9335981
-
项目类别:
-
资助金额:$60.53万
-
财政年份:2016
-
负责人:DAVID R ARCHER
-
依托单位:
Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy
-
批准号:8221131
-
项目类别:
-
资助金额:$50.46万
-
财政年份:2012
-
负责人:DAVID R ARCHER
-
依托单位:
Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy
-
批准号:8403679
-
项目类别:
-
资助金额:$43.89万
-
财政年份:2012
-
负责人:DAVID R ARCHER
-
依托单位:
Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy
-
批准号:8996584
-
项目类别:
-
资助金额:$47.46万
-
财政年份:2012
-
负责人:DAVID R ARCHER
-
依托单位:
The Pathogenesis of Sickle Cell Nephropathy
-
批准号:8005109
-
项目类别:
-
资助金额:$7.75万
-
财政年份:2010
-
负责人:DAVID R ARCHER
-
依托单位:
The Pathogenesis of Sickle Cell Nephropathy
-
批准号:7731051
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2009
-
负责人:DAVID R ARCHER
-
依托单位:
Allogeneic chimerism in murine sickle cell disease
-
批准号:6990435
-
项目类别:
-
资助金额:$1.87万
-
财政年份:2003
-
负责人:DAVID R ARCHER
-
依托单位:
Allogeneic chimerism in murine sickle cell disease
-
批准号:7076922
-
项目类别:
-
资助金额:$35.93万
-
财政年份:2003
-
负责人:DAVID R ARCHER
-
依托单位:
Allogeneic chimerism in murine sickle cell disease
-
批准号:6605104
-
项目类别:
-
资助金额:$37.22万
-
财政年份:2003
-
负责人:DAVID R ARCHER
-
依托单位:
Allogeneic chimerism in murine sickle cell disease
-
批准号:6773288
-
项目类别:
-
资助金额:$37.05万
-
财政年份:2003
-
负责人:DAVID R ARCHER
-
依托单位:
Allogeneic chimerism in murine sickle cell disease
-
批准号:6905639
-
项目类别:
-
资助金额:$38.7万
-
财政年份:2003
-
负责人:DAVID R ARCHER
-
依托单位:
Functional Analysis of Hematopoietic Stem Cell Origin
-
批准号:6395209
-
项目类别:
-
资助金额:$14.48万
-
财政年份:2001
-
负责人:DAVID R ARCHER
-
依托单位:
Functional Analysis of Hematopoietic Stem Cell Origin
-
批准号:6524331
-
项目类别:
-
资助金额:$13.12万
-
财政年份:2001
-
负责人:DAVID R ARCHER
-
依托单位:
IN UTERO TRANSPLANTATION IN BETA-THALASSEMIA
-
批准号:2901378
-
项目类别:
-
资助金额:$11.43万
-
财政年份:1998
-
负责人:DAVID R ARCHER
-
依托单位:
IN UTERO TRANSPLANTATION IN BETA-THALASSEMIA
-
批准号:6184118
-
项目类别:
-
资助金额:$10.81万
-
财政年份:1998
-
负责人:DAVID R ARCHER
-
依托单位:
IN UTERO TRANSPLANTATION IN BETA-THALASSEMIA
-
批准号:2600767
-
项目类别:
-
资助金额:$10.81万
-
财政年份:1998
-
负责人:DAVID R ARCHER
-
依托单位:
IN UTERO TRANSPLANTATION IN BETA-THALASSEMIA
-
批准号:6389893
-
项目类别:
-
资助金额:$10.81万
-
财政年份:1998
-
负责人:DAVID R ARCHER
-
依托单位:
IN UTERO TRANSPLANTATION IN BETA-THALASSEMIA
-
批准号:2797891
-
项目类别:
-
资助金额:$0.61万
-
财政年份:1998
-
负责人:DAVID R ARCHER
-
依托单位:
国内基金
海外基金
登录
查看更多内容
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
-
批准号:22007039
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:王黎明
-
依托单位:
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:朱义广
-
依托单位:
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
-
批准号:21372217
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:袁伟成
-
依托单位:
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
-
批准号:21172061
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2011
-
负责人:许新华
-
依托单位:
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
-
批准号:21176225
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:童少平
-
依托单位:
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
-
批准号:81072511
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2010
-
负责人:严江伟
-
依托单位:
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
-
批准号:30660215
-
项目类别:地区科学基金项目
-
资助金额:21.0万元
-
批准年份:2006
-
负责人:王世范
-
依托单位: